Enteris BioPharma (now MOD3 Pharma, acquired by Aptar Pharma) was a US-based CDMO specializing in the development and manufacture of difficult-to-formulate oral drug products. Operating from a 32,000 sq ft FDA-inspected, cGMP-compliant facility in northern New Jersey, the company offered custom formulation development and clinical trial manufacturing services.
Oral drug formulation, Clinical trial manufacturing, Difficult-to-formulate compounds, Peptelligence oral peptide technology
1 site worldwide
Involvement in 1 clinical trial
No certifications on file yet.
No reviews available yet.
No documents available.